miRNAs as potential biomarkers for subclinical atherosclerosis in Sjögren's disease.


Journal

RMD open
ISSN: 2056-5933
Titre abrégé: RMD Open
Pays: England
ID NLM: 101662038

Informations de publication

Date de publication:
22 Aug 2024
Historique:
received: 16 04 2024
accepted: 26 07 2024
medline: 24 8 2024
pubmed: 24 8 2024
entrez: 23 8 2024
Statut: epublish

Résumé

MicroRNAs (miRNAs) can regulate gene expression, controlling numerous cellular processes. Dysregulation of miRNA function is linked to various diseases, making them attractive diagnostic and therapeutic targets. Examples include hsa-miR-92a-3p, hsa-miR-126-3p, hsa-miR-143-3p, hsa-miR-145-5p and hsa-miR-204-5p, which are associated with endothelial function. Their prevalence in Sjögren's disease (SjD) is unknown. We assessed the prevalence of these miRNAs in serum of patients with SjD, correlating levels with cardiovascular risk factors and carotid intima-media thickness (cIMT) to evaluate their utility in risk stratification. 199 patients with SjD and 100 age and sex-matched healthy controls (HC) were included in the study. Five different miRNAs (hsa-miR-92a-3p; hsa-miR-126-3p; hsa-miR143-3p; hsa-miR-145-5p; hsa-miR-204-5p) were analysed by quantitative real-time PCR. The miRNA results were compared with known clinical and disease-related parameters. Four miRNAs showed significantly different expressions compared with HC. MiR-92a-3p was upregulated (p=0.025) and miR-126-3p (p=0.044), miR-143-3p (p=0.006) and miR-204-5p (p=0.009) downregulated in SjD compared with HC. The comparison between HC and SjD with/without organ involvement revealed descriptively increased miR-92a-3p levels in patients with SjD with organ involvement (p=0.087). Furthermore, miR-92a-3p levels correlated positively with cIMT as an expression of subclinical atherosclerosis (r=0.148, p=0.04). In conclusion, patients with SjD demonstrated differences in their expression of miRNAs linked to regulation of endothelial function. Reduction of specific miRNAs was associated with increased cardiovascular risk, suggesting a potentially protective role for these miRNAs. Furthermore, miR-92a-3p could be helpful for molecular detection of early-stage atherosclerosis and increased cardiovascular risk in SjD.

Sections du résumé

BACKGROUND BACKGROUND
MicroRNAs (miRNAs) can regulate gene expression, controlling numerous cellular processes. Dysregulation of miRNA function is linked to various diseases, making them attractive diagnostic and therapeutic targets. Examples include hsa-miR-92a-3p, hsa-miR-126-3p, hsa-miR-143-3p, hsa-miR-145-5p and hsa-miR-204-5p, which are associated with endothelial function. Their prevalence in Sjögren's disease (SjD) is unknown. We assessed the prevalence of these miRNAs in serum of patients with SjD, correlating levels with cardiovascular risk factors and carotid intima-media thickness (cIMT) to evaluate their utility in risk stratification.
METHODS METHODS
199 patients with SjD and 100 age and sex-matched healthy controls (HC) were included in the study. Five different miRNAs (hsa-miR-92a-3p; hsa-miR-126-3p; hsa-miR143-3p; hsa-miR-145-5p; hsa-miR-204-5p) were analysed by quantitative real-time PCR. The miRNA results were compared with known clinical and disease-related parameters.
RESULTS RESULTS
Four miRNAs showed significantly different expressions compared with HC. MiR-92a-3p was upregulated (p=0.025) and miR-126-3p (p=0.044), miR-143-3p (p=0.006) and miR-204-5p (p=0.009) downregulated in SjD compared with HC. The comparison between HC and SjD with/without organ involvement revealed descriptively increased miR-92a-3p levels in patients with SjD with organ involvement (p=0.087). Furthermore, miR-92a-3p levels correlated positively with cIMT as an expression of subclinical atherosclerosis (r=0.148, p=0.04).
CONCLUSION CONCLUSIONS
In conclusion, patients with SjD demonstrated differences in their expression of miRNAs linked to regulation of endothelial function. Reduction of specific miRNAs was associated with increased cardiovascular risk, suggesting a potentially protective role for these miRNAs. Furthermore, miR-92a-3p could be helpful for molecular detection of early-stage atherosclerosis and increased cardiovascular risk in SjD.

Identifiants

pubmed: 39179256
pii: rmdopen-2024-004434
doi: 10.1136/rmdopen-2024-004434
pii:
doi:

Substances chimiques

MicroRNAs 0
Biomarkers 0
MIRN126 microRNA, human 0
MIRN92 microRNA, human 0
MIRN204 microRNA, human 0
MIRN145 microRNA, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: Novartis did not contribute to the study design, analyses or data interpretation.

Auteurs

Nadine Zehrfeld (N)

Department of Rheumatology and Immunology, Hannover Medical School, Hannover, Lower Saxony, Germany.

Malin Abelmann (M)

Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany.
Institute of Molecular and Translational Therapeutic Strategies, Hannover Medical School, Hannover, Niedersachsen, Germany.

Sabrina Benz (S)

Department of Rheumatology and Immunology, Hannover Medical School, Hannover, Lower Saxony, Germany.

Tabea Seeliger (T)

Department of Neurology, Hannover Medical School, Hannover, Germany.

Fiona Engelke (F)

Department of Rheumatology and Immunology, Hannover Medical School, Hannover, Lower Saxony, Germany.

Thomas Skripuletz (T)

Department of Neurology, Hannover Medical School, Hannover, Germany.

Christian Baer (C)

Institute of Molecular and Translational Therapeutic Strategies, Hannover Medical School, Hannover, Niedersachsen, Germany.

Thomas Thum (T)

Institute of Molecular and Translational Therapeutic Strategies, Hannover Medical School, Hannover, Niedersachsen, Germany.

Torsten Witte (T)

Department of Rheumatology and Immunology, Hannover Medical School, Hannover, Lower Saxony, Germany.

Kristina Sonnenschein (K)

Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany.
Institute of Molecular and Translational Therapeutic Strategies, Hannover Medical School, Hannover, Niedersachsen, Germany.

Diana Ernst (D)

Department of Rheumatology and Immunology, Hannover Medical School, Hannover, Lower Saxony, Germany Ernst.Diana@mh-hannover.de.

Anselm Arthur Derda (AA)

Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH